Short-term and long-term outcomes of XXXX .

@entity1 @entity3123 @entity788 @entity3807 @entity5 @entity1157 @entity660 @entity134 @entity4903
OBJECTIVE: To examine the short-term and long-term clinical courses of @entity1 with @entity788 ( @entity788 ) who underwent different treatments and identify predictive factors for relapse of @entity788 after @entity134 therapy. METHODS: Clinical courses of 50 @entity788 @entity1 followed up for more than 1 year (median 40 months, range: 12-173 months) were examined. @entity1 were subdivided according to initial treatments as follows: surgical procedures in 10 @entity1 , supportive therapy in 11 @entity1 , and @entity134 therapy in 29 @entity1 . RESULTS: Of the surgically treated @entity1 , two underwent @entity134 therapy later because of progressive extensive @entity3807 , respectively. Five conservatively followed-up @entity1 were later given @entity134 therapy because of exacerbation of @entity788 involving the @entity1157 . @entity134 therapy was effective in all @entity1 . @entity4903 and salivary gland dysfunction improved after @entity134 therapy in 100, 85, and 75% of @entity1 , respectively. @entity788 relapsed in five @entity1 initially treated with @entity134 , and presence of hilar @entity1157 stenosis and elevated serum IgG4 levels were significantly associated with relapse. Two relapsed @entity788 @entity1 developed a pancreatic stone 2 and 3 years later. Although seven @entity1 died, no @entity1 died of @entity660 or developed @entity3123 . CONCLUSION: Most @entity788 @entity1 treated with @entity134 had good short-term and long-term outcomes clinically, morphologically, and functionally. Hilar @entity1157 stenosis and elevated serum IgG4 levels were predictors of @entity788 relapse after @entity134 therapy. As some @entity1 developed pancreatic stone formation or a @entity5 during or after @entity134 therapy, @entity788 @entity1 should be rigorously followed up.
